Evidence map›Paper›PMID 29633394›Full record

ArticleMolecular microbiology2018

For Cryptococcus neoformans, responding to the copper status in a colonization niche is not just about copper.

Daniel J Kosman

Open access · bronzeAbstract readComment
In one paragraph

Article in Molecular microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Proteomic Analysis of Copper Toxicity in Human Fungal PathogenFrontiers in cellular and infection microbiology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Daniel J KosmanDepartment of Biochemistry, The Jacobs School of Medicine and Biomedical Sciences, The University at Buffalo, Buffalo, NY 14203, USA.ORCID 0000-0003-3570-7682
Jacobs Institute · US

Funding

Ferroportin and APP: Regulation of Iron Trafficking at the Blood-Brain BarrierR01NS102337 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KOSMAN, DANIEL J. · 2017 to 2021
$2.0M
How Does APP Modulate Ferroportin? Developing Strategies to Determine MechanismR03NS095063 · NINDS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI KOSMAN, DANIEL J. · 2015 to 2016
$155k
NINDS NIH HHS R01 NS102337NINDS NIH HHS R03 NS095063
6 · The paper itself

Abstract

Most fungi express two transcription factors that regulate the expression of genes associated with copper uptake for nutritional needs, and with copper resistance when copper approaches a cytotoxic level. These factors are characterized by cysteine-rich motifs which are associated with copper-sensing, DNA-binding and release, and/or cytoplasmic retention. Cryptococcus neoformans differs from most in that it expresses a single such copper-sensing trans-factor, Cuf1, a protein that up-regulates copper uptake when copper is scarce, and up-regulates copper sequestration when cells become super-replete. For C. neoformans this is an essential task in as much as copper is relatively bioavailable in lung airways while the brain interstitium can be copper-limiting for growth. While fungal dependence on and sensitivity to copper have long been considered targets for anti-fungal chemistry, fungi have proven adept at finding 'work arounds' by using a chelated form of copper as nutrient or adapting to a copper-surfaced hospital bed by increased resistance. However, the cohort of Cuf1 targets identified in this report represent far more than just the uptake and sequestration machinery, but include additional loci that, perhaps, are less easily 'defended' by the fungus. Garcia-Santamarina et al. provide that list and thus lay the ground-work for developing novel anti-fungal reagents.

Indexed as

CopperCryptococcus neoformansCryptococcosisFungal ProteinsHumansTranscription FactorsCopperFungal ProteinsTranscription Factors

Identifiers

PMID29633394
PMCPMC5980769
OpenAlexW2796485705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.